Two Vanderbilt-Ingram Cancer Center (VICC) investigators have earned grant awards from The V Foundation for Cancer Research, continuing the foundation’s support for innovative cancer research initiatives at VICC.

Vanderbilt researchers have discovered a link between Helicobacter pylori infection, inflammation and gastric cancer that could suggest new anti-cancer therapies.

Nashville Predators goaltender Pekka Rinne, Predators executive leaders and mascot Gnash recently presented the proceeds of the team’s 365 Pediatric Cancer Fund to Monroe Carell Jr. Children’s Hospital at Vanderbilt.

Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis.

For breast cancer prevention, a new study provides evidence for lifestyle modification to reduce weight gain in adults.

Vanderbilt University Medical Center is the world’s first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation.

Jonathan Lehman, M.D., Ph.D., instructor in Medicine in the Division of Hematology/Oncology, has received a Career Development Award from LUNGevity, a nonprofit organization that provides support programs for lung cancer patients and families, public education and funding for innovative scientific research.